Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
17/09/2025 14:18
Arch Biopartners Inc ARCH.V: ARCH STRENGTHENS ITS POSITION AS A LEADING KIDNEY THERAPEUTICS COMPANY WITH THE ACQUISITION OF A BREAKTHROUGH PLATFORM TO DEVELOP NEW DRUGS TARGETING CHRONIC KIDNEY DISEASE (CKD) Source text: ID:nGNXchkx9R Further company coverage: ARCH.V
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide